SNY vs. VRTX, REGN, GSK, BMY, PFE, ZTS, ABT, TAK, NVS, and AZN
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), GSK (GSK), Bristol-Myers Squibb (BMY), Pfizer (PFE), Zoetis (ZTS), Abbott Laboratories (ABT), Takeda Pharmaceutical (TAK), Novartis (NVS), and AstraZeneca (AZN). These companies are all part of the "pharmaceutical preparations" industry.
Sanofi (NASDAQ:SNY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
10.0% of Sanofi shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Sanofi has higher revenue and earnings than Vertex Pharmaceuticals. Sanofi is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Sanofi has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Vertex Pharmaceuticals received 1518 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 75.62% of users gave Vertex Pharmaceuticals an outperform vote while only 53.23% of users gave Sanofi an outperform vote.
Sanofi currently has a consensus price target of $55.00, indicating a potential upside of 11.63%. Vertex Pharmaceuticals has a consensus price target of $432.18, indicating a potential downside of 1.03%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than Vertex Pharmaceuticals.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Sanofi's net margin of 10.52%. Vertex Pharmaceuticals' return on equity of 23.08% beat Sanofi's return on equity.
In the previous week, Sanofi had 15 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 38 mentions for Sanofi and 23 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.91 beat Sanofi's score of 0.64 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Summary
Vertex Pharmaceuticals beats Sanofi on 12 of the 18 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
